These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38913573)

  • 21. Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation.
    Fainberg HP; Moodley Y; Triguero I; Corte TJ; Sand JMB; Leeming DJ; Karsdal MA; Wells AU; Renzoni E; Mackintosh J; Tan DBA; Li R; Porte J; Braybrooke R; Saini G; Johnson SR; Wain LV; Molyneaux PL; Maher TM; Stewart ID; Jenkins RG
    Lancet Respir Med; 2024 Jul; ():. PubMed ID: 39025091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.
    Santos G; Fabiano A; Mota PC; Rodrigues I; Carvalho D; Melo N; Novais-Bastos H; Alexandre AT; Moura CS; Guimarães S; Pereira JM; Carvalho A; Morais A
    Pulm Pharmacol Ther; 2023 Dec; 83():102261. PubMed ID: 37758002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
    Maher TM; Molina-Molina M; Russell AM; Bonella F; Jouneau S; Ripamonti E; Axmann J; Vancheri C
    BMC Pulm Med; 2017 Sep; 17(1):124. PubMed ID: 28915874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.
    Cilli A; Uzer F; Sevinç C; Coşkun F; Ursavaş A; Öner Ş; Kose F
    Pulm Pharmacol Ther; 2021 Dec; 71():102099. PubMed ID: 34793978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis-Part B.
    Caliskan C; Seeliger B; Jäger B; Fuge J; Welte T; Terwolbeck O; Freise J; van Moorsel CHM; Zhang Y; Prasse A
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32630441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Automated airway quantification associates with mortality in idiopathic pulmonary fibrosis.
    Cheung WK; Pakzad A; Mogulkoc N; Needleman S; Rangelov B; Gudmundsson E; Zhao A; Abbas M; McLaverty D; Asimakopoulos D; Chapman R; Savas R; Janes SM; Hu Y; Alexander DC; Hurst JR; Jacob J
    Eur Radiol; 2023 Nov; 33(11):8228-8238. PubMed ID: 37505249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study.
    Zheng Q; Otahal P; Cox IA; de Graaff B; Campbell JA; Ahmad H; Walters EH; Palmer AJ
    Front Med (Lausanne); 2023; 10():1157706. PubMed ID: 37113607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis.
    Kaul B; Lee JS; Petersen LA; McCulloch C; Rosas IO; Bandi VD; Zhang N; DeDent AM; Collard HR; Whooley MA
    Chest; 2023 Aug; 164(2):441-449. PubMed ID: 36801465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in understanding idiopathic pulmonary fibrosis.
    Daccord C; Maher TM
    F1000Res; 2016; 5():. PubMed ID: 27303645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A machine learning based approach to identify carotid subclinical atherosclerosis endotypes.
    Chen QS; Bergman O; Ziegler L; Baldassarre D; Veglia F; Tremoli E; Strawbridge RJ; Gallo A; Pirro M; Smit AJ; Kurl S; Savonen K; Lind L; Eriksson P; Gigante B
    Cardiovasc Res; 2023 Dec; 119(16):2594-2606. PubMed ID: 37475157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication.
    Seeliger B; Carleo A; Wendel-Garcia PD; Fuge J; Montes-Warboys A; Schuchardt S; Molina-Molina M; Prasse A
    Front Pharmacol; 2022; 13():837680. PubMed ID: 36059968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
    Maher TM; Strek ME
    Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis.
    Choi MG; Choi SM; Lee JH; Kim JY; Song JW
    Respir Res; 2022 Dec; 23(1):334. PubMed ID: 36494685
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
    Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
    [No Abstract]   [Full Text] [Related]  

  • 38. Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial.
    Manzetti GM; Hosein K; Cecchini MJ; Kwan K; Abdelrazek M; Zompatori M; Rogliani P; Mura M
    BMC Pulm Med; 2021 Dec; 21(1):396. PubMed ID: 34863146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding Patterns of Adherence to Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis: Insights from an Italian Prospective Cohort Study.
    Iommi M; Gonnelli F; Bonifazi M; Faragalli A; Mei F; Pompili M; Carle F; Gesuita R
    J Clin Med; 2024 May; 13(9):. PubMed ID: 38731256
    [No Abstract]   [Full Text] [Related]  

  • 40. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.
    Jenkins RG; Simpson JK; Saini G; Bentley JH; Russell AM; Braybrooke R; Molyneaux PL; McKeever TM; Wells AU; Flynn A; Hubbard RB; Leeming DJ; Marshall RP; Karsdal MA; Lukey PT; Maher TM
    Lancet Respir Med; 2015 Jun; 3(6):462-72. PubMed ID: 25770676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.